Protagonist Therapeutics, Inc vs Abbvie Inc.
PTGX vs ABBV — side-by-side comparison from reported financials. PTGX leads 4, ABBV leads 6 of 10 comparable metrics.
Protagonist Therapeutics, Inc
PTGX · Healthcare
$143.00+2.21%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | PTGX | ABBV |
|---|---|---|
| Price | $143.00 | $276.43 |
| Market cap | $9.25B | $488B |
| Revenue (TTM) | $275M | $64.4B |
| Revenue growth | +20.1% | +1.8% |
| Net margin | 30.2% | 9.8% |
| Free cash flow | $131M | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | +113.3% | +19.8% |
| P/E | 112.2 | 77.4 |
| P/E vs own history (cheap-side %) | 21% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 12% | 96% |
| Altman Z-score | 139.54 | 2.33 |
| CV checks passed | 6 of 10 | 9 of 10 |
| Employees | 141 | 57,000 |
Full résumé-style profiles: PTGX CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.